Suchergebnisse

mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?

Eimer C, Gerullis H, Heuck C, Otto T.

Metastatic penile carcinoma - an update on the current diagnosis and treatment options.

Barski D, Georgas E, Gerullis H, Ecke T.

Targeted therapy in uro-oncology.

Otto T, Theuerkauf I, Tscheuschner S, Janusch B, Gerullis H.

Temsirolimus - mTOR als neue Zielstruktur in der Therapie des fortgeschrittenen Nierenzellkarzinoms.

Otto T, Gerullis H, Musch A.

Targeted therapy des metastasierten Nierenzellkarzinoms (mRCC).

Eimer C, Gerullis H, Otto T.

Wiederherstellung des Blasenschließmuskels mit körpereigenen Muskelzellen zur Kontinenz.

Otto T, Bagner JW, Eimer C, Gerullis H, Ramon A.

Vinflunin (Javlor). Second-Line-Therapie bei metastasiertem Urothelkarzinom nach Versagen platinhaltiger First-Line-Therapie.

Gerullis H, Otto T.

Comparison of prostate cancer survival in Germany and the United States: Can differences be attributed to differences in stage distributions?

Winter A, Sirri E, Jansen L, Wawroschek F, Kieschke J, Castro FA, Krilaviciute A, Holleczek B, Emrich K, Waldmann A, Brenner H; GEKID Cancer Survival Working Group.

Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles: The first in-human results.

Winter A, Kowald T, Paulo T, Goos Ph, Engels S, Gerullis H, Chavan A, Wawroschek F.

Augmentation of rat bladder with human amniotic membrane graft.

Barski D, Gerullis H, Winter A, Pintelon I, Timmermans J-P, Ramon A, Boros M, Varga G, Otto T.